Since the approval of poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) in BRCA1/2 mutant breast cancer in 2018, it has served as a risk-reducing medication and prolonged the prognosis-free survival distinctly. The gene discussed is BRCA1; the disease is breast carcinoma.